Rutgers New Jersey Medical School will be a clinical test site for a study assessing the long term risk of chronic kidney disease in patients who recover from COVID-19. The Multi-Center Assessment of Survivors for Kidney Disease after COVID-19 (MASKeD-COVID) study – conducted by the Division of Nephrology at Mount Sinai – will assess risk in up to 4,000 patients who have recovered from COVID-19 using the artificial-intelligence diagnostic system KidneyIntelX that can incorporate novel protein biomarkers and provide insight into the disease. Researchers will also study patients’ COVID-19 antibody levels over time, which will provide insights into the interaction between immune response and kidney-related complications. Initial research findings are expected to be reported in early 2021. To read the full story.
Recent Posts
- NIH Fellowship Writing Group: Call for Applications – Sign Up by 8/25
- Join The National Clinical Cohort Collaborative (N3C) Community Forum on 7/30
- NIH Fellowship Writing Group: Call for Applications – Sign Up by 8/25
- Rutgers Students Showcase AI-Driven Research Success Through NJ ACTS Summer Research Program
- Rutgers NJHealth Study Data Access Opportunity – Application Due July 6th!
Categories
- Community (2,500)
- Covid (1,001)
- CTO Events (6)
- News (3,174)
- Pilots (21)